Vir Biotechnology, Inc. Stock Price, News & Analysis

Vir Biotechnology (NASDAQ: VIR) reported Q3 2025 results and a corporate update on November 5, 2025. The company ended the quarter with $810.7 million in cash, cash equivalents and investments and expects runway into mid-2027. Clinical highlights include ECLIPSE 1 enrollment completing ~two months ahead of schedule with primary completion expected in Q4 2026 and topline data for ECLIPSE 1–3 expected in Q1 2027. VIR-5500 first patient dosed in an ARPI combination study and a comprehensive VIR-5500 data update is planned for Q1 2026. Q3 financials: revenue $0.2M, R&D $151.5M, SG&A $22.2M, and net loss $163.1M ($1.17/share). A conference call was held November 5, 2025.

Vir Biotechnology (Nasdaq: VIR) announced completion of enrollment in ECLIPSE 1, a Phase 3 trial testing the combination of tobevibart + elebsiran for chronic hepatitis delta (CHD). The company said ECLIPSE 1's last patient is expected to reach the primary endpoint in Q4 2026, with topline data expected in Q1 2027. ECLIPSE 2 and 3 are enrolling and remain on track. The release notes high unmet medical need for CHD, no approved U.S. treatments, and regulatory designations including FDA Breakthrough Therapy and Fast Track and EMA PRIME and orphan drug for the combination.

Vir Biotechnology (Nasdaq: VIR) will provide a corporate update and report third quarter 2025 financial results on November 5, 2025.

The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. A press release with the corporate update and financial results will be issued shortly after market close and posted on the Investors > News page of Vir Biotechnology's website. A live webcast will be available via the Events & Presentations page; participants must register in advance to receive a unique access link. An archived replay will be available about two hours after the event and remain archived for 30 days.

Vir Biotechnology (Nasdaq: VIR) announced on October 9, 2025 that the first patient has been dosed in Part 3 of its Phase 1 trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) for first-line pre-taxane metastatic castration-resistant prostate cancer (mCRPC).

VIR-5500 is a PRO-XTEN dual-masked T-cell engager targeting PSMA and is described as the only dual-masked PSMA-targeting TCE in clinical trials. The open-label, non-randomized study will assess safety, pharmacokinetics and preliminary anti-tumor activity. Earlier monotherapy data in heavily pre-treated mCRPC showed PSA reductions and a favorable safety profile during dose escalation.

Vir Biotechnology (NASDAQ: VIR) will present Week 48 endpoint results from the Phase 2 SOLSTICE study evaluating tobevibart (VIR-3434) alone and combined with elebsiran (VIR-2218) for chronic hepatitis delta at AASLD The Liver Meeting® 2025 in Washington, D.C., November 7-11.

Oral presentation: Week 48 SOLSTICE results on Nov 9, 2025 at 6:00 pm ET by Tarik Asselah, M.D., Ph.D. Poster: ECLIPSE registrational program design and objectives on Nov 8, 2025.

Vir Biotechnology (Nasdaq: VIR) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. CEO Marianne De Backer will engage in a fireside chat on September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York. Investors can access the live webcast through the company's website under the Events & Presentations section in the Investors area, with the recording remaining available for 30 days.

Vir Biotechnology (Nasdaq: VIR) reported Q2 2025 financial results and provided significant pipeline updates. The company has achieved key milestones, including the initiation of the ECLIPSE registrational program for chronic hepatitis delta and dosing the first patient in the Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager.

Financial highlights include a net loss of $111.0 million ($0.80 per share) and cash position of $892.1 million, expected to fund operations into mid-2027. Revenues were $1.2 million, down from $3.1 million in Q2 2024. R&D expenses decreased to $97.5 million from $105.1 million year-over-year.

The company now has three ongoing Phase 1 clinical trials of PRO-XTEN™ masked T-cell engagers, with promising early clinical data for VIR-5818 and VIR-5500 showing favorable safety profiles.

Vir Biotechnology (Nasdaq: VIR) has announced the successful initiation of all trials in its ECLIPSE registrational program for chronic hepatitis delta (CHD) with the enrollment of the first participant in ECLIPSE 3. The Phase 2b ECLIPSE 3 trial will evaluate the combination of tobevibart and elebsiran compared to bulevirtide in CHD patients.

The combination therapy has received multiple regulatory designations including Breakthrough Therapy and Fast Track from the FDA, and PRIME and orphan drug status from the EMA. The treatment aims to eliminate the virus through multiple mechanisms, addressing an urgent unmet medical need in CHD, which is the most severe form of chronic viral hepatitis with no approved treatments in the U.S.

Vir Biotechnology (Nasdaq: VIR) has initiated ECLIPSE 2, a pivotal Phase 3 clinical trial for chronic hepatitis delta (CHD). The trial will evaluate the combination of tobevibart and elebsiran versus continued bulevirtide monotherapy in patients who haven't achieved undetectable hepatitis delta virus RNA with bulevirtide treatment.

ECLIPSE 2 is part of Vir's global ECLIPSE registrational program launched in March 2025, designed to support marketing applications in the U.S. and Europe. The combination therapy has received multiple regulatory designations, including FDA Breakthrough Therapy and Fast Track, and EMA PRIME and orphan drug designations.